. Author manuscript; available in PMC: 2013 Oct 23.

Published in final edited form as: Gene Ther. 2012 Apr 5;20(3):255–261. doi: 10.1038/gt.2012.31

Table 1.

Dose level and schedule of cyclophosphamide used in humans and the corresponding doses in mice and hamsters

Human (mg kg ⁻¹)	Route	Intensity	Mouse (mg kg ⁻¹)	Hamster (mg kg ⁻¹)
3–5	Intravenous	Twice weekly	37–62	22–37
10–15	Intravenous	Every 7–10 days	123–185	74–111
40–50^a	Intravenous	Over 2–5 days	492–615	296–370
1–5^a	Oral	Daily	12–62	7–37

Human equivalent schedules used in this murine study. To convert human doses expressed in mg kg⁻¹ to animal doses, the human dose was multiplied by a factor of 12.3 for mouse and 7.4 for hamster. Clinical dose schedules were obtained from the Thomson Reuters (Healthcare) (Greenwood Village, CO, USA) DRUGDEX database.¹⁹ Human-to-animal conversion factors are based on recommendation by the US Food and Drug Administration for estimating the maximum safe starting dose in clinical trials.²⁰ Mice were dosed intraperitoneally at 120 mg kg⁻¹ daily for 4 days (human 10 mg kg⁻¹ × 4 doses) or by oral gavage at 40 mg kg⁻¹ daily for 8 days (human 3 mg kg⁻¹ × 8).